Migraine Minute News Update

Feeling drained with migraine? New research shows that more than half of people with migraine report fatigue, and it's tied to more frequent attacks and greater disability. Molly O'Brien breaks down the details in this Migraine Minute news update. Read More: https://bit.ly/4uNcspD   Script: More than half of people living with migraine say they also struggle with fatigue. That's according to a new study published in BMC's Journal of Headache and Pain. The study included 2,403 migraine patients, 57 percent of whom reported fatigue. They also found that people with fatigue had higher migraine frequency, worse sleep more disability, more severe cognitive symptoms, and more symptoms of anxiety and depression,  compared to those who didn't.* Study authors say that because fatigue is so common and impactful in migraine, it needs more attention. They suggested screening should be part of evaluations. *Although the study did not specify the exact cognitive symptoms, common ones people often experience include brain fog, memory problems, or trouble focusing.

Insurance hurdles like prior authorization and step therapy prevent migraine patients from finding relief, but could payer blocking strategies lead to more ER and hospital visits? Molly O'Brien breaks it down the latest in this Migraine Minute news update. Read the study: https://bit.ly/40OlvJ0 The Migraine Policy Forum: https://www.linkedin.com/company/the-headache-migraine-policy-forum/    Script: A study published in Headache shows insurance restrictions that deny access to migraine treatments aren't just frustrating…. These so-called "payer blocking" strategies were linked to more ER visits and hospital stays. Researchers reviewed information from more than 370,000 people with migraine who were denied access to prescribed migraine drugs at least two times because of payer blocking insurance restrictions like step therapy or prior authorization. They found payer blocking affected about one in five patients and was more common among those with lower income or lower education levels. They also found people with a history of payer blocking were more likely to visit the ER or be hospitalized for migraine-related or other health issues. Lead author Dr. Dawn Buse said, "These insurance barriers don't just delay care, they undermine quality of life, especially for those with fewer resources. Reducing them is essential to improving migraine outcomes."

As April is Autism Awareness Month, we're sharing new research on the relationship between migraine and autism. A study published in Headache shows people with autism are more likely to experience migraine or headache, and symptoms may be more severe. Molly O'Brien breaks it down in this Migraine Minute news update. Read the Study: https://bit.ly/3PyF3P3 Creative Commons: https://creativecommons.org/licenses/by-nc/4.0/ Script: A study published in Headache found that people with autism are more likely to also have headache or migraine than those without autism. Looking at two data sets, researchers found that headache and migraine severity were increased in people with autism compared to those without. Also of note, people with autism and migraine were more likely to have had negative experiences in childhood, such as bullying, being a victim of violence, poor health, anxiety, depression, and concussion. Researchers note that migraine may be underdiagnosed in those living with autism due to communication barriers and that migraine screening may help with earlier diagnosis and treatment in those with autism.

Facial pain or pressure? It might not be a sinus infection. New findings from AMD's HEADS Registry suggest migraine may be behind these symptoms for some. Molly O'Brien breaks down the research in this Migraine Minute News Update. Read more: https://bit.ly/4aE9Dis Do you have sinus pain, dizziness, or ringing in the ears? The HEADS Registry is collecting patient experiences to improve care. Learn more: migrainedisorders.org/heads-registry Creative Commons: https://creativecommons.org/licenses/by/4.0/

Analysis of the COMPEL study shows that onabotulinumtoxinA (Botox) can help reduce migraine days, lower migraine-related disability, and improve quality of life in diverse populations of chronic migraine patients. Molly O'Brien breaks down the data in this Migraine Minute News Update. Read More: https://bit.ly/4trLxyK Researchers acknowledge that the term "race" doesn't accurately capture diverse cultural differences, noting that future research should distinguish between race and ethnicity. *This content is not sponsored and is intended for educational purposes only. It does not constitute an endorsement by the Association of Migraine Disorders for BOTOX® products.

Can vestibular rehab help vestibular migraine? A new review suggests that it may ease dizziness and improve daily functioning. Molly O'Brien breaks down the information in this Migraine Minute News Update. Read More: https://bit.ly/4aOHo18 Script: A new review published in Headache, The Journal of Head and Face Pain, looked at whether or not vestibular rehabilitation could be effective for vestibular migraine. Researchers looked at seven studies involving more than 400 people with VM. The studies focused on how dizziness affects daily life, using a standardized questionnaire called the Dizziness Handicap Inventory. Overall, people who did vestibular rehab saw improvements in dizziness and quality of life. Results differed from study to study, so additional research is needed to confirm the benefits and figure out which exercises are most helpful.

Migraine preventive treatment benefits may go beyond fewer headache days. A new study links erenumab to improved symptoms of anxiety, depression, and poor sleep quality in some people with migraine. Molly O'Brien has the details in this Migraine Minute News Update. Read More: https://bit.ly/3LJl3r7 Script: A new study suggests that one migraine treatment may offer benefits beyond less headache days. Researchers found that the CGRP monoclonal antibody erenumab, sold under the brand name Aimovig, not only reduces migraine frequency… but may improve symptoms of anxiety, depression, and poor sleep quality in some adults with migraine. Participants took 140MG of erenumab monthly. Over the course of the 24 weeks those who had at least a 50 percent drop in monthly migraine days ALSO saw improved anxiety, depression, and sleep quality.  The authors say improvements are likely driven by better migraine control rather than a direct effect of the medication. Researchers also say this study highlights how good migraine prevention may improve overall well-being and quality of life.

In a study published in Headache, researchers identified 36 symptoms that can appear hours before a migraine attack. In this MM news update, Molly O'Brien highlights the most common symptoms, when they occur, and how recognizing these early signs can help people better treat their migraine attacks. Read more: https://bit.ly/4ozrewr Transcript: A new study published in Headache is among the first to explore the migraine prodrome from the patient's perspective. Researchers held in-depth interviews with 20 people who have migraine, all to better understand what happens before the headache phase begins and how bothersome those symptoms are. The study identified 36 prodrome symptoms…. with nausea, fatigue, sensitivity to light and sound, neck pain/stiffness, irritability, dizziness or vertigo, sensitivity to temperature, brain fog, and trouble concentrating being the most commonly reported. On average, each participant experienced about 13 prodrome symptoms. And, 72% of prodrome symptoms occurred one to six hours before the onset of head pain. The study authors say understanding these early signs may help determine a treatment window…. And if patients can use treatment before severe pain begins, there is potential to reduce migraine burden. That's your MM news update. I'm Molly O'Brien.

Our recent survey shows some people aren't aware migraine can progress—and many fear their attacks can get worse. Molly O'Brien breaks down the survey results in this MM news update. Do you worry about pain and symptoms getting worse? Let us know in the comments. Learn more: https://www.migrainedisorders.org/migraine-disorders/migraine-treatments/ Transcript: Did you know that migraine can be a progressive disease? For some people, attacks can become more frequent, and symptoms or pain may worsen over time. People may even transition from episodic to chronic migraine. The Association of Migraine Disorders held a survey to see how much the migraine community knows about the potential for progression. Among 459 respondents, 18% did not know that migraine could worsen over time.  50% were aware but hadn't always realized it could progress or become more severe. 68% said they were moderately to extremely worried that their migraine frequency or severity might increase. While migraine doesn't get worse for everyone, proper treatment can help prevent progression.  If you're nervous about your attacks getting worse, be sure to talk to your healthcare provider and visit AMD's treatments page to learn more. That's your MM news update, I'm Molly O'Brien.

Treating migraine in pregnancy can be challenging since many drugs carry risks. The good news is that the FDA updated precautions on a drug-free wearable device. Molly O'Brien has the story in this Migraine Minute News Update. Read More: http://bit.ly/4mMtfo1  Script: The FDA recently updated its precautionary language on the Nerivio neuromodulation device… removing the note that it has not been studied for use during pregnancy. Based on a 2023 study published in Headache, the FDA changed the precaution to: "Users should consult their healthcare provider if they are pregnant or intend to get pregnant prior to using the device."  As we previously reported in an August 2023 Migraine Minute News update, the study's results suggest that the Nerivio device is a safe treatment for migraine during pregnancy, does not increase the risk for adverse pregnancy outcomes, and may offer a drug-free treatment option for migraine during pregnancy.

First-of-its-kind study: A new study suggests that a combination of THC + CBD works better than placebo, THC alone, or CBD alone for reducing migraine pain and symptoms. Molly O'Brien breaks it down in this Migraine Minute News Update. Read More: https://bit.ly/4qvpuWo Script: For the first time, researchers tested cannabis in a placebo-controlled trial for migraine… and results suggest it could be effective. A recent study found that when treating migraine attacks, a vaporized combination of THC and CBD worked better than THC alone, CBD alone, or a placebo. THC alone helped with pain, but not other symptoms, while CBD alone did not show any benefit. Study participants who used the THC/CBD combination also saw improvements in light and sound sensitivity, but not nausea or vomiting. No serious adverse events were reported. In an interview with MedScape, one researcher noted that people experienced benefits without using higher, recreational doses of cannabis.       

A new real-world study shows atogepant (sold under brand name Qulipta) may quickly reduce migraine days—even for those who haven't responded to other treatments. Molly O'Brien has more in this Migraine Minute News Update! Read more: http://bit.ly/3UcEuJN CC License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Script: The GIANT study, published inThe Journal of Headache and Pain, offers real-world evidence that atogepant is a safe, well-tolerated, and effective for migraine prevention—among those whose prior treatments didn't work. Researchers looked at the impact of 60 mg of atogepant, taken once daily in people with either high-frequency episodic or chronic migraine. Many of the participants had already tried at least three other preventive treatments… including CGRP monoclonal antibodies. Results? At 12 weeks, on average, participants saw a decrease of 6 migraine days and 11 headache days per month. In fact, nearly 60% of experienced at least a 50 percent drop in migraine days. Pain intensity, disability, and use of acute drugs also dropped. Some saw improvement in migraine frequency within the first week.

Can diabetes and weight loss drugs help with migraine relief? A new study suggests GLP-1 medications may significantly reduce migraine days. @ Molly O'Brien has more in this Migraine Minute News Update. Read More: http://bit.ly/4kGN4eO Image and license to use: Headache. 2025; 00: 1-8. http://bit.ly/47imNQO Script: GLP-1s….a drug class widely used for diabetes and weight loss treatment, may also help migraine. A small study published in Headache looked at liraglutide as an add-on treatment for unresponsive migraine in people with obesity who have tried at least two preventive migraine treatments. The study tracked 31 adults with high-frequency episodic or chronic migraine. After taking a daily dose of the drug for three months, on average, they saw monthly headache days drop from about 20 to just under 11—a significant improvement. What may be surprising… is that the benefit came with insignificant weight loss. 

A major study found that oral triptans work better for the acute treatment of migraine, than newer drugs. Molly O'Brien breaks it all down in this Migraine Minute News Update. Read more: https://bit.ly/3Wu6ZnP Images and License to use: BMJ 2024;386:e080107http://bit.ly/4ljgU9x Script: A major international study published in the British Medical Journal found triptans to be the most effective acute treatment for migraine. Researchers analyzed 137 clinical trials involving nearly 90,000 adults… comparing 17 oral treatments. They looked at how many people were pain-free two hours post-dose and how many were still pain-free at 24 hours, as well as the safety and tolerability of the treatments. They looked at how many people were pain-free at 2 hours and 24 hours, as well as the safety and tolerability of the treatments. The top performer? Eletriptan — it was shown to be the most effective for both rapid and sustained pain relief. Other high performers included rizatriptan, sumatriptan, and zolmitriptan. Those four triptans consistently outperformed newer acute treatment options like lasmiditan, ubrogepant, and rimegepant. These newer acute treatments worked about as well as acetaminophen and most non-steroidal anti-inflammatory drugs. Also, results showed that not all NSAIDs work the same for migraine.  

A study in the Journal of Psychopharmacology found a surprising connection between psychedelic use and frequent bad headaches. Could psilocybin play a role in headache treatment? Molly O'Brien explains in this Migraine Minute News Update.  Read more: http://bit.ly/40k21Mu Script: A new study in the Journal of Psychopharmacology shows that people who've used psychedelics like LSD or psilocybin may be less likely to experience frequent bad headaches. Researchers analyzed data from a large group of people in the UK and found that those who reported a lifetime use of classic psychedelics were 25% less likely to report frequent bad headaches compared to those who had never used them. So why might that be? One thought is that both psychedelics and conventional migraine drugs (like triptans) work on serotonin receptors in the brain. While the study doesn't prove that psychedelics directly prevent headaches, It DOES add to growing evidence that psychedelics may be a helpful tool to treat headache disorders. And a quick note, psychedelics are illegal on a federal level in the US. That's your migraine minute news update, I'm Molly O'Brien. Images: Sage Journals. The Journal of Psychopharmacology. doi: 10.1177/02698811251324 License to use: https://creativecommons.org/licenses/by/4.0/

Scientists are learning how stress may trigger a series of brain responses that could be linked to migraine, at least in mice. Molly O'Brien has more in this Migraine Minute News Update. Source: PACAP38/mast-cell-specific receptor axis mediates repetitive stress-induced headache in mice Script: A study published in the Journal of Headache and Pain explains how stress can lead to migraine pain. Research in mice found that stress increases a brain chemical called PACAP-38. This chemical activates specific cells that release inflammatory substances. This series of events can affect the trigeminovascular system, which may trigger migraine pain. The study's author notes that blocking or interrupting this pathway could offer a new way to treat or prevent migraine attacks.

Two innovative DHE-based migraine treatments just earned FDA approval—offering some Americans new options for managing attacks. Molly O'Brien has details in this #MigraineMinute News Update. Read More: https://bit.ly/4kgmXMt and https://bit.ly/3SYet0c *DHE is not safe for the management of hemiplegic migraine, migraine with brainstem aura, in people with certain comorbidities, or in those who take certain medications. Script: Many Americans with migraine now have two new treatment options, thanks to recent FDA approvals of Brekiya and Atzumi. Both drugs utilize Dihydroergotamine or DHE. While DHE for migraine has been around for decades, these two new drugs have new delivery methods. Brekiya is the first and only DHE auto-injector approved for the acute treatment of migraine and cluster headache in adults.  Atzumi is the first and only DHE nasal powder approved for the acute treatment of migraine with or without aura in adults. It's important to note that DHE has several safety implications and contraindications and must be prescribed by a healthcare provider.

Celebrating the Fourth of July with migraine is not easy. The holiday can be packed with sensory overload and migraine triggers. In this Migraine Minute, Molly O'Brien shares tips to help you enjoy the celebration while protecting your health. Check out our updated triggers webpage: https://bit.ly/4kFOZRf Reference: https://pubmed.ncbi.nlm.nih.gov/19329386/ Script: While the Fourth of July can be a fun holiday to celebrate in the States, it can be tough for folks with migraine. Why? Well, there are so many factors that can be stacked against you. Think about it, heat, big crowds, staying up late, BBQ foods and drinks that might have triggering ingredients…Not to mention the bright flashes and loud bangs of fireworks. Research even shows exposure to sulfur dioxide, a common byproduct of fireworks, may trigger migraine attacks. If you have migraine and still want to enjoy the holiday, here are some tips from our migraine community: Stay hydrated, wear ear plugs, watch fireworks from afar or skip all together, bring migraine safe food and drinks to your cook out, wear sunglasses or migraine glasses, and keep a consistent routine. Don't forget to check out AMD's updated triggers page, where you can learn more about common migraine triggers and how to manage them.

New research shows CGRP monoclonal antibody treatment may not prevent migraine attacks triggered by the neuropeptide PACAP-38. This study suggests PACAP-38 may act through a different pathway and could become a future preventive option for people who don't respond to CGRP-based treatments. Molly O'Brien explains in this Migraine Minute News Update.  Read More: https://bit.ly/4ivy3LG Images courtesy: Springer Nature. The Journal of Headache and Pain. doi: 10.1186/s10194-025-02022-2 Creative Commons license: https://creativecommons.org/licenses/by-nc-nd/4.0/ Script: Does PACAP 38 Work Differently Than CGRP? A new study published in the Journal of Headache and Pain found that migraine attacks can be triggered by the neuropeptide PACAP-38 despite pre-treatment with a CGRP monoclonal antibody. Researchers gave 38 participants with migraine an infusion of eptinezumab—a CGRP monoclonal antibody—or placebo, followed by PACAP-38. The results showed no difference in the incidence of migraine attacks between the two groups. This study suggests that PACAP-38 may trigger migraine attacks through a different pathway than CGRP. Treatments targeting PACAP-38 may offer a new preventive option for people who've had limited or no success with CGRP monoclonal antibodies.

A study published in JAMA Neurology shows that monthly erenumab injections may help treat medication overuse headache (MOH) in people with chronic migraine. While the 140 mg dose was effective for treating MOH, the 70 mg dose did not show a meaningful difference compared to placebo. Molly O'Brien explains in this Migraine Minute News Update. Read More: https://bit.ly/4jCusxk Image Courtesy: JAMA Neurology doi:10.1001/jamaneurol.2024.3043 Transcript: A study published in JAMA Neurology looked at the safety and efficacy of a CGRP monoclonal antibody for treating Medication Overuse Headache in people with chronic migraine. Results show that erenumab– sold under brand name Aimovig- can lead to lasting remission of MOH, reduce the need for pain medication, and improve daily functioning over six months. The study included 584 people with chronic migraine who also had medication overuse headache. At 6 months, 69.1% of those who received 140 mg injections of erenumab monthly no longer met the criteria for medication overuse headache compared to 52.6% of people in the placebo group. It should be noted that the study did not include people who had medication-overuse headache from opioid use.

Most people with migraine go through trial and error to find a preventive treatment that works. But researchers at the Mayo Clinic may have found a way to change that. Using AI, they developed a tool to predict how someone might respond to certain migraine medications—particularly CGRP monoclonal antibodies. Molly O'Brien has more in this Migraine Minute News Update. Read More: https://bit.ly/40uKyjE    

Rapid relief from a preventive migraine treatment? A study published in Neurology shows that one oral gepant medication may start working right away to prevent migraine attacks. Molly O'Brien fills you in, in this Migraine Minute News Update. Read more: https://bit.ly/3Wvb1fU

The FDA has approved a new drug for the acute treatment of migraine with or without aura in adults. Molly O'Brien has the details and when it becomes available in this Migraine Minute News update.    Learn More: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-symbravor-meloxicam

Researchers in Boston found that CGRP-blocking drugs commonly used for migraine may help with endometriosis pain and lesion size. Molly O'Brien has the details in this Migraine Minute news update recognizing Endometriosis Awareness Month.  Read More: https://bit.ly/4jp0cG2 AMD Comorbidities Library: https://bit.ly/3CIrLtd

Cluster Headache Awareness Day is March 21st. In this Migraine Minute News Update Molly O'Brien explains findings from a study that found cluster headache, fibromyalgia, and migraine are frequently comorbid conditions. Learn More: https://bit.ly/42pSNQS

According to a study published in Neurology, when compared to placebo, this gepant led to significantly greater ability to function normally and a greater reduction in activity limitation when taken during the prodrome phase of an attack. Molly O'Brien has the details in this Migraine Minute News Update.  Read More: https://bit.ly/3BY2J9d

Kids age 8+ now have access to a non-drug migraine treatment option. In this Migraine Minute News Update, Molly O'Brien explains the FDA clearance of Theranica's Nerivio device for acute and preventive migraine treatment in kids.   Read more: https://bit.ly/4fRXRk5

Researchers have identified elevated levels of the gene MERTK, (which is linked to cluster headaches) and its ligand Gal-3, in the nerve tissues of rats and in blood samples of people with cluster headache. In this Migraine Minute News Update Molly O'Brien breaks down what it means for people living with Cluster. Read More: https://bit.ly/3ZXzTQ0

Contrary to previous research, a study published in Neurology finds among women, there is no link between migraine and the risk of developing Parkinson's disease. Molly O'Brien explains in this Migraine Minute News Update.   Want to know more about Migraine and Parkinson's disease? Check out this article in AMD's Comorbidities library: https://bit.ly/3XZSaJB  

A small study published in the New England Journal of Medicine finds a single IV infusion of a Monoclonal Antibody targeting PACAP reduced monthly migraine days better than placebo. In this Migraine Minute News Update Molly O'Brien explains. Read More: https://bit.ly/3XXXNrR

The National Institute of Neurological Disorders and Stroke awards a $2.4 million grant to researchers at the University of Texas Health to examine the link between the circadian clock and severe headache disorders. Molly O'Brien has details in this Migraine Minute News Update. Read more: bit.ly/3BsNwfT

A study finds treatment with anti-CGRP mAbs does not significantly affect blood pressure or increase the occurrence of hypertension (compared to general population trends) in people 60+. In this Migraine Minute, Molly O'Brien explains the findings.  Read More: bit.ly/3zpcYSB 

A study found that anti-CGRP monoclonal antibodies not only reduced absenteeism & presenteeism in Spain, they were found to be cost-effective too. Read more: http://bit.ly/3S1KS5Y Image courtesy: DOI 10.1186/s10194-024-01727-0

A new study looks at the efficacy and safety of two gepant medications. Molly O'Brien will share the study findings in this Migraine Minute News update.  Read the study: bit.ly/4cwJQar Image courtesy: Sage Journals. Cephalalgia doi:10.1177/03331024241235156  

Light sensitivity and poor sleep quality in people with migraine, could the two be related? In a study published in the Journal of Headache and Pain, researchers looked at the impact photophobia may have on sleep quality in people with migraine. Molly O'Brien breaks it down in this Migraine Minute News Update. Learn more: bit.ly/4cIJMUD

Caffeine habit? A new study looks at the link between episodic migraine and regular caffeine intake. Molly O'Brien will fill you in, in this latest Migraine Minute News Update. Learn more about the study at bit.ly/4bzLyXu

The US FDA clears another wearable drug-free migraine treatment device. In this Migraine Minute News Update, Molly O'Brien will tell you all about a new TENS device available for people with episodic migraine. Read more: https://bit.ly/4aEZFe9

Many people with chronic migraine worry that their monthly preventive medication won't work as well at the end of the month as it did at the beginning. New research shows that two injectable CGRP monoclonal antibodies do not wear off at the end of the month. Molly O'Brien has the details in this #MigraineMinute News Update.   Read more: bit.ly/3w95WQn

A study in the Lancet found one oral gepant to be safe and effective in people with episodic migraine who have failed two to four classes of preventive treatments. Molly O'Brien explains in this Migraine Minute News Update. Read the study here: https://bit.ly/3w3ZM45  

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1 *The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25, 14 (2024). https://doi.org/10.1186/s10194-024-01721-6. The graphical abstract has been slightly modified.

 Researchers at the University of California Los Angeles found changes in blood flow in the retina might explain why some people have visual migraine symptoms. Molly O'Brien has the details in this Migraine Minute News update.  Learn more: https://bit.ly/3xou7uw , https://bit.ly/4aErYZN

AMD is thrilled to share what we've learned so far from our HEADS Registry! Molly O'Brien goes over the exclusive new data in this Migraine Minute News Update. The HEADS Registry serves as a crucial resource for researchers and clinicians. It's not too late to share your experience, by doing so, you can help pave the way for more effective therapies, enhanced and personalized patient care, and improved quality of life. Learn more at migrainedisorders.org/heads-registry/

Obesity is often connected with an increase in migraine frequency, severity and disability. In this Migraine Minute News Update, Molly O'Brien gives details on what we're learning about one MAB drug and its effectiveness in people with migraine and comorbid obesity.   Read more here: https://bit.ly/3ONRu6m  

New results from the OVERCOME study, published in Neurology,  Found that just over 31 percent of people living with migraine often or very often feel stigmatized. Molly O'Brien will fill you in on the details in this Migraine Minute News Update. 

Nerivio becomes the first drug-free Migraine Treatment to Receive Commercial Insurance Coverage in the US. Molly O'Brien explains in this Migraine Minute News Update. Read more here: https://bit.ly/3T6lKvL

We know Migraine and ADHD are comorbid, but there is still a lot left to learn about how they are connected. @Molly O'Brien will fill you in on new research that explores ADHD symptoms in people with migraine.  Sources: https://bit.ly/3vNm6hT

Feel a migraine attack coming on? New research shows these three types of medications may be more effective than ibuprofen for many people. Molly O'Brien will share details in this Migraine Minute News Update. Read more here: https://bit.ly/47HEwh9

New research shows taking one type of gepant medication during the prodrome phase may reduce the risk of a severe headache. Molly O'Brien will fill you in, in this Migraine Minute News Update. Read the study here: https://bit.ly/3GLKEtT

Are you looking for new ways to manage migraine in the new year? Practicing mindfulness may help. Molly O'Brien explains in this Migraine Minute News Update.  More info: https://bit.ly/3RRdVd1

Singer and actress Ally Brooke Hernandez rose to international fame as a member of the all-female singing group Fifth Harmony. In an interview with People en Espanol, Hernandez spoke out about how migraine has impacted her life and career. Molly O'Brien will fill you in on this Migraine Minute News Update. Read the full story: https://bit.ly/3FG2Q7s